Contact Us
Careers
Press Releases
LinkedIn
About Us
Executive Leadership Team
Board of Directors
Scientific Advisory Board
Medicines
Pipeline
Anaphylm™
Libervant®
Technologies
Services
Our Responsibilities
Investors
Press Releases
Events & Presentations
Corporate Governance
SEC Filings
Stock Information
Analyst Coverage
Quarterly Results
Contact Us
Careers
Press Releases
Linkedin
Meaningful
improvements.
Innovative
delivery.
We're advancing medicines to bring meaningful improvements to patients' lives through innovative science and delivery technologies.
Learn about our pipeline
2.5+ billion doses
and counting
Our PharmFilm® technology is behind trusted, high-quality brands that have simplified treatment regimens and improved patients’ lives
Learn about our medicines
Two breakthrough
technologies.
Endless possibilities.
Our core technologies feature PharmFilm, with a proven track record of transformational drug delivery, and AdrenaVerse—our next frontier of innovation.
Learn about our technologies
Manufacturing
products sold
worldwide
Backed by 20+ years of experience, we manufacture and package trusted products for global brands, all made in the USA.
Learn about services
01.
Pipeline
02.
Medicines
03.
Technologies
04.
Services
Our success is proven
Learn more about us
1
FDA approvals
with products available on six continents
1
+ patents
filed in the U.S. and worldwide
0
+ billion
PharmFilm® doses shipped worldwide
0
+ years
since the company was founded
Learn more about us
Latest News
View all press releases
May 13, 2026
Aquestive Therapeutics Reports First Quarter 2026 Financial Results and Provides Business Update
Read More
May 12, 2026
Aquestive Therapeutics Completes $150 Million Debt Refinancing with Oaktree
Read More
May 06, 2026
Aquestive Therapeutics to Report First Quarter 2026 Financial Results and Recent Business Highlights on May 13 and Host Conference Call on May 14 at 8:00 a.m. ET
Read More
March 30, 2026
Aquestive Therapeutics Announces Completion of Type A Meeting with FDA for Anaphylm™ (dibutepinephrine) Sublingual Film
Read More
March 20, 2026
Aquestive Therapeutics Announces New Role of Lori J. Braender and Appointment of Thomas A. Zalewski as Chief Legal Officer and Chief Compliance Officer
Read More
March 09, 2026
Aquestive Therapeutics Announces Grant of Inducement Award Pursuant to Nasdaq Listing Rule 5635(c)(4)
Read More
INVESTOR RELATIONS
Simplified medicine delivery
Our patient-centric approach guides the way
NASDAQ: AQST
4.73
USD
0.60
(
14.53
%) Today
Events and presentations
ESG Sustainability Report
Press releases
SEC Filings